Arrowhead Pharmaceuticals (ARWR) Advances REDEMPLO Launch, Is The Stock Still Undervalued?
Arrowhead Pharmaceuticals (ARWR) drew fresh investor attention after REDEMPLO, its plozasiran therapy for familial chylomicronaemia syndrome, was listed in the Lauer-Taxe database following European marketing authorisation supported by Phase 3 PALISADE trial data.
See our latest analysis for Arrowhead Pharmaceuticals.
Against this regulatory milestone, Arrowhead Pharmaceuticals has seen strong momentum, with a 30 day share price return of 24.79% and a year to date share price return of 31.89%, while the 1 year total shareholder return is very large at 342.62%.
If you are looking for more ideas in high growth areas of healthcare, this could be a useful moment to scan 42 healthcare AI stocks
Bulls argue Arrowhead Pharmaceuticals now has a validated rare disease asset and a broad RNAi pipeline. Bears point to ongoing losses and execution risk. Which side does the current valuation evidence support as the stock re-rates?
Most Popular Narrative: 18.9% Undervalued
Arrowhead Pharmaceuticals closed at $89.41, while the most followed narrative puts fair value at $110.18, which sets up a clear valuation gap for investors to assess.
Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for treatments driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.
Want to see how a high growth revenue profile, changing profit margins and a premium future earnings multiple all fit together for Arrowhead Pharmaceuticals? The narrative lays out one cohesive set of assumptions that ties these moving parts into a single fair value view.
Result: Fair Value of $110.18 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story for Arrowhead Pharmaceuticals can change quickly if key partners delay milestone payments or if upcoming regulatory decisions on plozasiran and zodasiran are disappointing.
Find out about the key risks to this Arrowhead Pharmaceuticals narrative.
Another View on Arrowhead Pharmaceuticals Using Sales Multiples
The most followed narrative points to Arrowhead Pharmaceuticals being 18.9% undervalued, yet the current P/S of 18.9x tells a different story. That multiple is above the peer average of 17.3x, above the US Biotechs industry at 11.1x, and slightly higher than the fair ratio of 18.8x, which tilts more toward valuation risk than clear upside at today’s price. How comfortable are you paying above both peers and the fair ratio for this growth profile?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism and concern around Arrowhead Pharmaceuticals, this may be a useful time to examine the details yourself and consider acting while sentiment is still forming. Start by weighing the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Arrowhead Pharmaceuticals?
If you stop with Arrowhead Pharmaceuticals, you only see part of the picture. Broaden your watchlist using focused screeners that highlight different strengths and risk profiles.
- Target potential mispricings by scanning 52 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
- Strengthen your defensive side by reviewing 78 resilient stocks with low risk scores that score well on resilience and downside protection.
- Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com